The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2021Modulation of Epigenetic Regulator HDAC4 as a Parkinson’s Treatment
Study Rationale:
Scientists can take skin cells from people with Parkinson’s disease (PD), turn them into stem cells, and then engineer them into dopamine neurons, the cell type lost in PD. Our... -
Target Advancement Program, 2021Targeting the Neurovascular Unit to Prevent Dissemination and Progression of Parkinson’s Disease
Study Rationale:
The cells residing in the brain are physically separated from the blood stream by the blood-brain barrier, a specialized grouping of cells that reduces transfer from the blood... -
Target Advancement Program, 2021Use of Therapeutic Nanoparticles to Inhibit Toxic Aggregation of Alpha-Synuclein
Study Rationale:
A hallmark of Parkinson’s disease (PD) is the abnormal accumulation of clumps of alpha-synuclein in nerve cells. These improperly folded protein clumps contribute to the symptoms of... -
Therapeutic Pipeline Program, 2021Studies to Assess the Potential of Gold “Nanocrystals” for the Treatment of Parkinson’s Disease
Study Rationale:
CNM-Au8 is a new type of nanomedicine that consists of tiny crystals made of pure gold. The multifaceted surface of these gold nanocrystals provides a platform for metabolic... -
Biomarkers, 2021Measurement of Mitochondrial DNA in Early Stages of Parkinson’s Disease
Study Rationale:
People with a form of idiopathic REM sleep behavior disorder (iRBD) experience nightmares and lash out physically during a stage of sleep when the body's muscles are normally... -
Therapeutic Pipeline Program, 2021Novel Inhibitors of Protein Aggregation as Potential Therapeutics for Parkinson’s Disease
Study Rationale:
The protein alpha-synuclein can aggregate in brain cells, which leads to brain cell death in Parkinson’s disease (PD). We plan to investigate a novel class of drugs — called protein...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.